Nawsherwan Mohammad: Recognizing TTP Before the ADAMTS13 Result Arrives
Nawsherwan Mohammad, Consultant Hematopathologist at Nanakaly Hospital, shared a post on LinkedIn about a recent article by Stephen MacDonald et al., published in BJHaem, adding:
“Suspected TTP is a medical emergency – don’t wait for ADAMTS13 to treat when clinical suspicion is high.
A practical summary of the 2026 BSH laboratory guidance on thrombotic thrombocytopenic purpura:
- Think TTP when thrombocytopenia plus microangiopathic haemolytic anaemia occur together.
- Look for marked thrombocytopenia, schistocytes, reticulocytosis, elevated LDH, low haptoglobin, and usually normal coagulation.
- Send a pre-treatment ADAMTS13 sample – ideally 3.2% sodium citrate, not EDTA – but never delay treatment.
- ADAMTS13 activity less than 10 IU/dL strongly supports TTP.
- 10–20 IU/dL is a grey zone, not an automatic negative.
- If less than 10 IU/dL, test anti-ADAMTS13 antibodies within 72 hours.
- Antibody-negative does not prove congenital TTP – genetic testing is required.
- For monitoring, use the same assay platform whenever possible.
Key message: rapid recognition, early sampling, and urgent treatment save lives.”
Title: Diagnosis and monitoring of thrombotic thrombocytopenic purpura: Guidance for laboratories from the British Society for Haematology
Authors: Stephen MacDonald, Thomas Pitchford, Deepak Singh, Rebekah Fretwell, P. Vince Jenkins, Caroline Lawrence, Richard Gooding, Sean Platton

Stay updated with Hemostasis Today.
-
Nov 20, 2026, 17:27Adam Bryant: Great Science, Valuable Connections and a Wonderful Haematology Community at Blood 2026
-
Nov 20, 2026, 17:25Gurpreet Kaurr: Scientific Discussions, New Perspectives and Inspiration at HAEMATOCON 2026
-
Nov 20, 2026, 17:24Bispecific FVIIIa-Mimetic Antibodies in Haemophilia A – CRH French Reference Center for Hemophilia Lyon
-
Nov 20, 2026, 17:23Khalid Rehman: Psychosocial Burden Among Caregivers of Patients with Beta-Thalassemia Major in Pakistan
-
Nov 20, 2026, 17:20Dhinesh Selvaraju: Caplacizumab Becomes the First FDA-Approved Treatment for Pediatric aTTP
-
Nov 20, 2026, 17:19Paris Margaritis: Presenting Preclinical Data on GENV-HEM at the WFH Workshop
-
Nov 20, 2026, 17:18WFH Opens Public Comment on Draft Guidelines for Hemostatic Agents and Prophylaxis
-
Nov 20, 2026, 17:18Ketan Asawale: Consensus on the Management of Cancer-Associated Thrombosis in India
-
Nov 20, 2026, 17:16Ajay Samkaria: The Evolution of Hemostasis Diagnostics with the ACL TOP 70 Series